American BIO Medica CORP: insider trades · United States · SEC (Form 4)

About American BIO Medica CORP

American Bio Medica Corp. is a small US-listed company operating in the healthcare and diagnostics space, with SEC coverage that includes insider transaction reporting on Form 4. The company is a United States corporation, incorporated in New York in 1986 under the name American Micro Media, Inc., and renamed American Bio Medica Corporation in 1992 as it shifted toward rapid diagnostic testing. Its operating address is in Kinderhook, New York, and the business is best characterized as a niche micro-cap diagnostics manufacturer with limited market visibility and typically modest trading liquidity in the US public markets. For investor context, it is a US issuer in the NYSE/NASDAQ ecosystem, even though it should be viewed as a very small-cap, highly specialized name rather than a mainstream large- or mid-cap healthcare stock. The company’s core business is the development, manufacture, and sale of lateral flow immunoassay tests, primarily for the immediate detection of drugs in urine and oral fluid. These point-of-collection testing products are used by employers, law enforcement, government agencies, healthcare providers, laboratories, and education-sector customers. In addition to direct product sales, American Bio Medica also provides contract manufacturing and related services, including strip manufacturing, assembly, packaging, and certain R&D activities for third parties. Its SEC filings also indicate that it distributes other products related to drug and alcohol testing, point-of-care diagnostics, and, in some reporting periods, rapid COVID-19 tests. From a competitive standpoint, the company has historically highlighted a meaningful differentiator: its products are manufactured in the United States, whereas many competitors produce outside the country, often in China. That domestic manufacturing profile may appeal to customers that value supply-chain resilience, speed of delivery, and US-based production. At the same time, the market remains competitive and heavily commoditized, especially in rapid drug testing, where pricing pressure is significant and differentiation depends on regulatory compliance, product reliability, service quality, and customer relationships. American Bio Medica’s recent SEC disclosures suggest a continuing focus on its established test lines and on cost discipline, rather than on aggressive expansion into new therapeutic or diagnostic categories. The company appears to operate with a lean structure, which is typical of a micro-cap issuer with a narrow product set. For investors in France, Belgium, and Switzerland, the key analytical takeaway is that American Bio Medica is a niche US diagnostics company with a long operating history, a clear specialization in rapid drug testing, and a business model that is highly sensitive to contract wins, reimbursement and compliance trends, and execution in a crowded, price-sensitive market.